Comparison of the sustained response of Peg-Intron/ribavirin [peginterferon alfa-2b + ribavirin] combination therapy in genotype 1-infected hepatitis C patients for non-extended versus 24-week extended treatment after 24 weeks pilot treatment in Taiwan
Phase of Trial: Phase IV
Latest Information Update: 01 Jul 2014
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Schering-Plough
- 23 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jan 2008 The expected completion date for this trial is now 1 Jul 2008.
- 22 Aug 2007 Status changed from recruiting to in progress.